Disulfiram-loaded lactoferrin nanoparticles for treating inflammatory diseases
In this study, we developed a DSF-LF nanoparticulate system (DSF-LF NP) for combining the immunosuppressive activities of both DSF and LF. DSF-LF NPs could effectively block pyroptosis and inflammatory cytokine release from macrophages. Treatment with DSF-LF NPs showed remarkable therapeutic effects on lipopolysaccharide (LPS)-induced sepsis. In addition, this therapeutic strategy was also applied to treat ulcerative colitis (UC), and substantial treatment efficacy was achieved in a murine colitis model. The underlying mode of action of these DSF-LF-NPs may contribute to efficiently suppressing macrophage-mediated inflammatory responses and ameliorating the complications caused by sepsis and UC. As macrophage pyroptosis plays a pivotal role in inflammation, this safe and effective biomimetic nanomedicine may offer a versatile therapeutic strategy for treating various inflammatory diseases by repurposing DSF.PMID:34561552 | DOI:10.1038/s41401-021-00770-w
Source: Acta Pharmacologica Sinica - Category: Drugs & Pharmacology Authors: An-Te Ou Jia-Xin Zhang Yue-Fei Fang Rong Wang Xue-Ping Tang Peng-Fei Zhao Yu-Ge Zhao Meng Zhang Yong-Zhuo Huang Source Type: research
More News: Addiction | Alcoholism | COVID-19 | Drugs & Pharmacology | Inflammatory Bowel Disease | Men | Nanotechnology | Study | Ulcerative Colitis